Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:80457rdf:typepubmed:Citationlld:pubmed
pubmed-article:80457lifeskim:mentionsumls-concept:C0026630lld:lifeskim
pubmed-article:80457lifeskim:mentionsumls-concept:C0039194lld:lifeskim
pubmed-article:80457lifeskim:mentionsumls-concept:C0039195lld:lifeskim
pubmed-article:80457lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:80457lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:80457lifeskim:mentionsumls-concept:C0175668lld:lifeskim
pubmed-article:80457lifeskim:mentionsumls-concept:C0079411lld:lifeskim
pubmed-article:80457lifeskim:mentionsumls-concept:C0173022lld:lifeskim
pubmed-article:80457pubmed:issue3lld:pubmed
pubmed-article:80457pubmed:dateCreated1978-11-18lld:pubmed
pubmed-article:80457pubmed:abstractTextFollowing in vitro stimulation of murine sarcoma virus Moloney isolate (M-MuSV)-immune spleen cells with syngeneic antigenically related Moloney leukemia cells, highly efficient cytotoxic T-lymphocytes (CTL's) were generated. The cytotoxic effect was directed only against H-2-compatible target cells bearing M-MuSV tumor-associated antigens (TAA). However, in a cold target competition assay a weak but detectable capacity to block CTL activity was also obtained when allogeneic Moloney leukemia cells were added. Moreover, when M-MuSV-immune spleen cells from mice inoculated with virus 14 days previously were stimulated by allogeneic Moloney leukemia cells, a strong cytotoxic effect toward syngeneic and allogeneic tumor cells bearing M-MuSV TAA was elicited.lld:pubmed
pubmed-article:80457pubmed:languageenglld:pubmed
pubmed-article:80457pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:80457pubmed:citationSubsetIMlld:pubmed
pubmed-article:80457pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:80457pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:80457pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:80457pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:80457pubmed:statusMEDLINElld:pubmed
pubmed-article:80457pubmed:monthSeplld:pubmed
pubmed-article:80457pubmed:issn0027-8874lld:pubmed
pubmed-article:80457pubmed:authorpubmed-author:Chieco-Bianch...lld:pubmed
pubmed-article:80457pubmed:authorpubmed-author:CollavoDDlld:pubmed
pubmed-article:80457pubmed:authorpubmed-author:ColombattiAAlld:pubmed
pubmed-article:80457pubmed:authorpubmed-author:BiasiGGlld:pubmed
pubmed-article:80457pubmed:authorpubmed-author:ParenteEElld:pubmed
pubmed-article:80457pubmed:issnTypePrintlld:pubmed
pubmed-article:80457pubmed:volume61lld:pubmed
pubmed-article:80457pubmed:ownerNLMlld:pubmed
pubmed-article:80457pubmed:authorsCompleteYlld:pubmed
pubmed-article:80457pubmed:pagination885-90lld:pubmed
pubmed-article:80457pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:80457pubmed:meshHeadingpubmed-meshheading:80457-An...lld:pubmed
pubmed-article:80457pubmed:meshHeadingpubmed-meshheading:80457-Mi...lld:pubmed
pubmed-article:80457pubmed:meshHeadingpubmed-meshheading:80457-Sa...lld:pubmed
pubmed-article:80457pubmed:meshHeadingpubmed-meshheading:80457-Le...lld:pubmed
pubmed-article:80457pubmed:meshHeadingpubmed-meshheading:80457-Fe...lld:pubmed
pubmed-article:80457pubmed:meshHeadingpubmed-meshheading:80457-Ma...lld:pubmed
pubmed-article:80457pubmed:meshHeadingpubmed-meshheading:80457-Ep...lld:pubmed
pubmed-article:80457pubmed:meshHeadingpubmed-meshheading:80457-Tu...lld:pubmed
pubmed-article:80457pubmed:meshHeadingpubmed-meshheading:80457-Mo...lld:pubmed
pubmed-article:80457pubmed:meshHeadingpubmed-meshheading:80457-An...lld:pubmed
pubmed-article:80457pubmed:meshHeadingpubmed-meshheading:80457-Mi...lld:pubmed
pubmed-article:80457pubmed:meshHeadingpubmed-meshheading:80457-An...lld:pubmed
pubmed-article:80457pubmed:meshHeadingpubmed-meshheading:80457-Mi...lld:pubmed
pubmed-article:80457pubmed:meshHeadingpubmed-meshheading:80457-Cy...lld:pubmed
pubmed-article:80457pubmed:meshHeadingpubmed-meshheading:80457-T-...lld:pubmed
pubmed-article:80457pubmed:meshHeadingpubmed-meshheading:80457-H-...lld:pubmed
pubmed-article:80457pubmed:year1978lld:pubmed
pubmed-article:80457pubmed:articleTitleSecondary in vitro generation of cytolytic T-lymphocytes (CTL's) in the murine sarcoma virus system. Virus-specific CTL induction across the H-2 barrier.lld:pubmed
pubmed-article:80457pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:80457pubmed:publicationTypeIn Vitrolld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:80457lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:80457lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:80457lld:pubmed